DF
FATE icon

Dunhill Financial’s Fate Therapeutics FATE Stock Holding History

Dunhill Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.82K Hold
3,180
– – ﹤0.01% 676
2025
Q4 		$3.13K Hold
3,180
– – ﹤0.01% 672
2025
Q3 		$4.01K Hold
3,180
– – ﹤0.01% 587
2025
Q2 		$3.56K Hold
3,180
– – ﹤0.01% 590
2025
Q1 		$2.51K Hold
3,180
– – ﹤0.01% 697
2024
Q4 		$5.25K Hold
3,180
– – ﹤0.01% 529
2024
Q3 		$11.1K Hold
3,180
– – 0.01% 357
2024
Q2 		$10.4K Hold
3,180
– – 0.01% 280
2024
Q1 		$23.3K Hold
3,180
– – 0.02% 162
2023
Q4 		$11.9K Buy
+3,180
New +$7.51K 0.01% 185

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dunhill Financial's FATE Position: Q1 2026 in Review

Dunhill Financial held its Fate Therapeutics (FATE) position steady in Q1 2026 at 3,180 shares worth $3.82K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Dunhill Financial first reported a position in FATE in Q4 2023 and has held it in 10 quarters since. The position peaked at $23.3K in Q1 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Dunhill Financial held 3,180 shares of Fate Therapeutics worth $3.82K as of Q1 2026.
  • Dunhill Financial left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #676 holding.
  • Dunhill Financial first reported a position in Fate Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Dunhill Financial's Fate Therapeutics position peaked at $23.3K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.